Petvivo Holdings, Inc. and Digital Landia Corp. Announce Groundbreaking Strategic Alliance Agreement to Pioneer Agentic AI for Animal Communication
PetVivo Holdings (OTCQB: PETV) has formed a strategic alliance with Digital Landia Corp. to integrate pet healthcare with AI technology. The partnership involves PetVivo exchanging $150,000 in restricted common stock for a 2% equity stake in Digital Landia and receiving 3 million Digital Landia tokens.
The collaboration centers on Pet AI, a platform that analyzes animal behavior with 97% accuracy through vocalizations, body language, and physiological signals. PetVivo's products, including SPRYNG® with OsteoCushion® Technology and Precise PRP®, will be exclusively promoted when the AI detects joint-related afflictions in pets.
The platform offers a freemium model with basic translation features and a $9.99/month subscription tier. The partnership targets a significant market, including 900 million dogs worldwide (25% with arthritis), 370 million cats, and 60 million horses, positioning PetVivo's joint treatment solutions within an AI-driven pet care ecosystem.
PetVivo Holdings (OTCQB: PETV) ha formato un'alleanza strategica con Digital Landia Corp. per integrare la salute degli animali domestici con la tecnologia AI. La partnership prevede che PetVivo scambi 150.000 dollari in azioni comuni ristrette per una partecipazione del 2% in Digital Landia, ricevendo in cambio 3 milioni di token Digital Landia.
La collaborazione si concentra su Pet AI, una piattaforma che analizza il comportamento degli animali con un'accuratezza del 97% attraverso vocalizzazioni, linguaggio del corpo e segnali fisiologici. I prodotti di PetVivo, inclusi SPRYNG® con tecnologia OsteoCushion® e Precise PRP®, saranno promossi esclusivamente quando l'AI rileva affezioni articolari negli animali domestici.
La piattaforma offre un modello freemium con funzionalità di traduzione di base e un abbonamento di livello a 9,99 dollari al mese. La partnership mira a un mercato significativo, che include 900 milioni di cani in tutto il mondo (di cui il 25% affetti da artrite), 370 milioni di gatti e 60 milioni di cavalli, posizionando le soluzioni di trattamento articolare di PetVivo all'interno di un ecosistema di cura degli animali domestici guidato dall'AI.
PetVivo Holdings (OTCQB: PETV) ha formado una alianza estratégica con Digital Landia Corp. para integrar la salud de las mascotas con la tecnología de IA. La asociación implica que PetVivo intercambie 150,000 dólares en acciones comunes restringidas por una participación del 2% en Digital Landia y reciba 3 millones de tokens de Digital Landia.
La colaboración se centra en Pet AI, una plataforma que analiza el comportamiento animal con un 97% de precisión a través de vocalizaciones, lenguaje corporal y señales fisiológicas. Los productos de PetVivo, incluyendo SPRYNG® con tecnología OsteoCushion® y Precise PRP®, serán promovidos exclusivamente cuando la IA detecte afecciones articulares en las mascotas.
La plataforma ofrece un modelo freemium con características de traducción básicas y un nivel de suscripción de 9.99 dólares al mes. La asociación apunta a un mercado significativo, que incluye 900 millones de perros en todo el mundo (25% con artritis), 370 millones de gatos y 60 millones de caballos, posicionando las soluciones de tratamiento articular de PetVivo dentro de un ecosistema de cuidado de mascotas impulsado por IA.
PetVivo Holdings (OTCQB: PETV)는 애완동물 건강과 AI 기술을 통합하기 위해 Digital Landia Corp.와 전략적 제휴를 형성했습니다. 이 파트너십은 PetVivo가 Digital Landia의 2% 지분을 위해 150,000달러의 제한된 보통주를 교환하고 300만 개의 Digital Landia 토큰을 받는 것을 포함합니다.
협력의 중심은 Pet AI로, 이 플랫폼은 음성, 신체 언어 및 생리적 신호를 통해 동물 행동을 97% 정확도로 분석합니다. PetVivo의 제품인 SPRYNG®와 OsteoCushion® 기술, Precise PRP®는 AI가 애완동물의 관절 관련 질병을 감지할 때 독점적으로 홍보됩니다.
이 플랫폼은 기본 번역 기능을 제공하는 프리미엄 모델과 월 9.99달러의 구독 수준을 제공합니다. 이 파트너십은 전 세계 9억 마리의 개(25%가 관절염), 3억 7천만 마리의 고양이, 6천만 마리의 말이 포함된 상당한 시장을 목표로 하여 PetVivo의 관절 치료 솔루션을 AI 기반 애완동물 관리 생태계 내에 위치시킵니다.
PetVivo Holdings (OTCQB: PETV) a formé une alliance stratégique avec Digital Landia Corp. pour intégrer la santé des animaux de compagnie avec la technologie AI. Le partenariat implique que PetVivo échange 150 000 dollars en actions ordinaires restreintes contre une participation de 2% dans Digital Landia et reçoit 3 millions de jetons Digital Landia.
La collaboration se concentre sur Pet AI, une plateforme qui analyse le comportement animal avec une précision de 97% à travers les vocalisations, le langage corporel et les signaux physiologiques. Les produits de PetVivo, y compris SPRYNG® avec technologie OsteoCushion® et Precise PRP®, seront exclusivement promus lorsque l'IA détecte des affections articulaires chez les animaux de compagnie.
La plateforme propose un modèle freemium avec des fonctionnalités de traduction de base et un abonnement à 9,99 $ par mois. Le partenariat vise un marché significatif, incluant 900 millions de chiens dans le monde (25 % souffrant d'arthrite), 370 millions de chats et 60 millions de chevaux, positionnant les solutions de traitement articulaire de PetVivo au sein d'un écosystème de soins pour animaux de compagnie dirigé par l'IA.
PetVivo Holdings (OTCQB: PETV) hat eine strategische Allianz mit Digital Landia Corp. gebildet, um die Gesundheitsversorgung von Haustieren mit KI-Technologie zu integrieren. Die Partnerschaft umfasst, dass PetVivo 150.000 Dollar in beschränkten Stammaktien im Austausch für eine 2%ige Beteiligung an Digital Landia und 3 Millionen Digital Landia-Token erhält.
Die Zusammenarbeit konzentriert sich auf Pet AI, eine Plattform, die das Verhalten von Tieren mit einer Genauigkeit von 97% durch Lautäußerungen, Körpersprache und physiologische Signale analysiert. Die Produkte von PetVivo, einschließlich SPRYNG® mit OsteoCushion®-Technologie und Precise PRP®, werden ausschließlich gefördert, wenn die KI gelenkbezogene Erkrankungen bei Haustieren erkennt.
Die Plattform bietet ein Freemium-Modell mit grundlegenden Übersetzungsfunktionen und einer Abonnementstufe von 9,99 Dollar pro Monat. Die Partnerschaft zielt auf einen bedeutenden Markt ab, der 900 Millionen Hunde weltweit (25% mit Arthritis), 370 Millionen Katzen und 60 Millionen Pferde umfasst, und positioniert die Gelenkbehandlungslösungen von PetVivo innerhalb eines KI-gesteuerten Ökosystems für die Haustierpflege.
- Secured exclusive advertising rights for joint affliction products on Pet AI platform
- Access to vast market: 900M dogs, 370M cats, 60M horses globally
- Integration with 97% accurate AI technology for pet diagnosis
- Acquired 2% equity stake in Digital Landia
- Will receive 3M Digital Landia tokens
- Investment of $150,000 in restricted stock required
- Dependent on successful launch and adoption of Pet AI platform
- Revenue generation tied to subscription model adoption ($9.99/month)
MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) (the "Company" or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for animals and Digital Landia Corp. a pioneer in Agentic AI solutions, today announced a transformative strategic alliance agreement. The collaboration centers on Pet AI, Digital Landia’s revolutionary open-source platform that deciphers animal behavior through real-time analysis of vocalizations, body language, and physiological signals captured via smartphone cameras. This technology, which achieves
Partnership Structure and Strategic Benefits
Under the agreement, PetVivo will exchange
SPRYNG® with OsteoCushion® Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP®, is a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
“Digital Landia’s Agentic AI represents a paradigm shift in how we understand our pets,” said John Lai, CEO of PetVivo Holdings, Inc. “By aligning our clinically proven therapies with this technology, we position PetVivo at the intersection of AI innovation and veterinary care. We anticipate Pet AI will rival mainstream AI applications in adoption rates, creating unparalleled visibility for our brands, including SPRYNG and PrecisePRP.”
Pet AI: Bridging the Communication Gap
The Pet AI platform employs self-learning algorithms that analyze peer-reviewed research, user-submitted data, and real-time inputs to interpret emotions and physical states in dogs, cats, horses, and avian species. Key features include:
- Freemium Model: A free tier offers basic translation (e.g., barks, purrs) without memory retention.
- Subscription Tier (
$9.99 /month): Enables continuous learning tailored to individual pets while contributing anonymized data to improve global accuracy. - Veterinarian Tools: Clinics can create custom AI agents to advise clients, schedule follow-ups, and recommend treatments like Spryng™ injections.
Market Opportunity and Global Pet Population Trends
The partnership taps into a vast addressable market, leveraging the following global pet ownership data:
- Dogs: 900 million worldwide (85 million in the U.S.), with
25% suffering from arthritis. - Cats: 370 million globally (55 million in the U.S.), increasingly prone to age-related joint issues.
- Horses: 60 million worldwide (7 million in the U.S.), many requiring joint support.
With
Integrated Care and Revenue Model
PetVivo will collaborate with veterinarians to deploy AI agents that:
- Identify early signs of joint afflictions or degenerative conditions using visual and/or motion analysis.
- Recommend Spryng™ as a medical device for the management of joint related afflictions, such as osteoarthritis.
- Recommend PrecisePRP for conditions that may benefit from the administration of platelet rich plasma (PRP).
- Connect clinics with pet owners via targeted ads, driving subscription upgrades and in-app purchases of PetVivo products.
Token holders will receive discounts on PetVivo products, fostering loyalty within Digital Landia’s ecosystem.
For more information about PetVivo Holdings, Inc. and our revolutionary products, Spryng with OsteoCushion Technology and PrecisePRP, please contact info1@petvivo.com or visit https://petvivo.com/ or http://www.sprynghealth.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is the equity stake PetVivo (PETV) acquired in Digital Landia through the strategic alliance?
How accurate is the Pet AI platform in translating animal communication?
What is the subscription cost for Pet AI's premium features?
How many Digital Landia tokens will PETV receive through this partnership?
What is the target market size for PETV's joint treatment products through this AI partnership?
